98%
921
2 minutes
20
Background: Three percent hypertonic saline (3% HTS) is used to treat several critical conditions such as severe and symptomatic hyponatremia and increased intracranial pressure. It has been traditionally administered through a central venous catheter (CVC). The avoidance of peripheral intravenous infusion of 3% HTS stems theoretically from the concern about the ability of the peripheral veins to tolerate hyperosmolar infusions. The aim of this systematic review and meta-analysis is to assess the rate of complications associated with the infusion of 3% HTS using peripheral intravenous access.
Methods: We conducted a systematic review and meta-analysis to assess the rate of complications related to the peripheral infusion of 3% HTS. We searched several databases for available studies that met the criteria until February 24th, 2022. We included ten studies conducted across three countries examining the incidence of infiltration, phlebitis, venous thrombosis, erythema, and edema. The overall event rate was calculated and transformed using the Freeman-Tukey arcsine method and pooled using the DerSimonian and Laird random-effects model. I was used to evaluate heterogeneity. Selected items from Newcastle-Ottawa Scale were used to assess the risk of bias in each included study.
Results: A total of 1200 patients were reported to have received peripheral infusion of 3% HTS. The analysis showed that peripherally administered 3% HTS has a low rate of complications. The overall incidence of each of the complications was as follows: infiltration 3.3%, (95% C.I. = 1.8-5.1%), phlebitis 6.2% (95% C.I. = 1.1-14.3%), erythema 2.3% (95% C.I. = 0.3-5.4%), edema 1.8% (95% C.I. = 0.0-6.2%), and venous thrombosis 1% (95% C.I. = 0.0-4.8%). There was one incident of venous thrombosis preceded by infiltration resulting from peripheral infusion of 3% HTS.
Conclusions: Peripheral administration of 3% HTS is considered a safe and possibly preferred option as it carries a low risk of complications and is a less invasive procedure compared to CVC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amjms.2023.04.025 | DOI Listing |
Eur J Endocrinol
May 2025
Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, 4031 Basel, Switzerland.
Introduction: For the treatment of severe symptomatic hyponatremia, the European Society of Endocrinology (ESE) guidelines (2014) recommend a bolus-wise strategy using hypertonic saline (HTS). However, there are recent controversies regarding the risk of overcorrection and osmotic demyelination syndrome (ODS), leading to significant heterogeneity in practice. The aim of this survey was to evaluate clinical practices and perspectives of endocrinologists across Europe in managing severe symptomatic hyponatremia.
View Article and Find Full Text PDFTher Adv Med Oncol
May 2025
Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
Background: Immune checkpoint inhibitors are used either as monotherapy or in combination with cytotoxic agents in metastatic gastric cancer (mGC). Studies show that circadian rhythms are essential for immune system functions, including anticancer immunity.
Objectives: This study evaluated whether the time of day of nivolumab infusion altered the efficacy of mGC treatment.
Electrolyte Blood Press
December 2024
Department of Internal Medicine, College of Medicine, Dankook University, Republic of Korea.
Background: Elevated intracranial pressure (ICP) is a potentially life-threatening condition requiring prompt intervention. While both mannitol and hypertonic saline (HTS) are commonly used hyperosmotic agents for treating elevated ICP, there is insufficient evidence comparing their renal safety profiles and overall effectiveness. This study protocol outlines a pragmatic randomized trial to compare protocol-based 11.
View Article and Find Full Text PDFBackground: Severe symptomatic hyponatraemia is potentially life-threatening and hypertonic saline (HTS) is effective at rapidly correcting serum sodium. Several clinical guidelines have aimed to standardise the administration of HTS. However, evidence supporting the guidelines is limited, and concerns have been raised regarding the potential for overcorrection.
View Article and Find Full Text PDFNeurosurg Rev
February 2024
Department of Health Statistics, Naval Medical University, No. 800 Xiangyin Road, Shanghai, 200433, China.
Osmotic therapy has been recognized as an important treatment option for patients with traumatic brain injury (TBI). Nevertheless, the effect of hypertonic saline (HTS) remains unknown, as findings are primarily based on a large database. This study aimed to elucidate the effect of HTS on the clinical outcomes of patients with TBI admitted to the intensive care unit (ICU).
View Article and Find Full Text PDF